Beam Therapeutics (BEAM) grants CFO stock options for 63,500 shares

Rhea-AI Filing Summary

Beam Therapeutics Inc. reported a stock option grant to its Chief Financial Officer, Emany Sravan Kumar. On 01/31/2026, he received a stock option to buy 63,500 shares of Beam Therapeutics common stock at an exercise price of $27.62 per share, expiring on 01/31/2036.

The option vests in equal monthly installments over the 48 months following the grant date, conditioned on his continued service with Beam Therapeutics through each vesting date. Following this grant, he directly held 63,500 derivative securities related to Beam Therapeutics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Emany Sravan Kumar

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	63,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 63,500 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Emany Sravan Kumar

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.62	01/31/2026		A		63,500		(1)	01/31/2036	Common Stock	63,500	$0	63,500	D

Explanation of Responses:

1. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BEAM report for Emany Sravan Kumar?

Beam Therapeutics reported a stock option grant to CFO Emany Sravan Kumar. He received options for 63,500 shares of common stock on 01/31/2026, documented as an acquisition of derivative securities on a Form 4 insider trading report.

How many Beam Therapeutics shares are covered by the CFO’s new options?

The CFO’s stock option covers 63,500 shares of Beam Therapeutics common stock. These are derivative securities giving him the right to buy that number of shares, subject to the stated vesting schedule and the option’s 01/31/2036 expiration date.

What is the exercise price of the BEAM stock options granted to the CFO?

The stock options granted to the Beam Therapeutics CFO have an exercise price of $27.62 per share. This is the price he must pay to purchase each share if he exercises vested options before the 01/31/2036 expiration date.

What is the vesting schedule for the Beam Therapeutics CFO stock options?

The stock option vests in equal monthly installments over 48 months following the 01/31/2026 grant date. Vesting is conditioned on the CFO’s continued service with Beam Therapeutics through each monthly vesting date specified in the award terms.

When do the newly granted Beam Therapeutics stock options expire?

The newly granted Beam Therapeutics stock options to the CFO expire on 01/31/2036. He may exercise vested portions any time before that expiration, consistent with the equal monthly vesting schedule over the 48 months after the grant date.

Is the Beam Therapeutics CFO’s option holding reported as direct or indirect ownership?

The Form 4 reports the Beam Therapeutics CFO’s 63,500 stock options as directly owned. The ownership form is listed as “D” for direct, and no footnote attributes these derivative securities to any separate entity or indirect beneficial owner.